|
|
|
|
|
|
Late |
McCreary et al., medRxiv, doi:10.1101/2021.11.30.21266756 (Preprint) |
death, ↓93.0%, p=0.009 |
Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19 |
|
Details
Prospective study comparing subcutaneous and intravenous casirivimab/imdevimab, and comparing to a PSM matched control set, showing significantly lower mortality and hospitalization with treatment. Controls were matched with EUA-eligible .. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| McCreary et al., medRxiv, doi:10.1101/2021.11.30.21266756 (Preprint) |
| Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19 |
|
Prospective study comparing subcutaneous and intravenous casirivimab/imdevimab, and comparing to a PSM matched control set, showing significantly lower mortality and hospitalization with treatment. Controls were matched with EUA-eligible risk factors only, authors were unable to determine symptom severity.
![]()
risk of death, 93.0% lower, RR 0.07, p = 0.009, treatment 1 of 652 (0.2%), control 29 of 1,304 (2.2%), propensity score matching.
risk of death/hospitalization, 56.0% lower, RR 0.44, p < 0.001, treatment 22 of 652 (3.4%), control 101 of 1,304 (7.7%), propensity score matching.
risk of hospitalization, 48.0% lower, RR 0.52, p = 0.005, treatment 22 of 652 (3.4%), control 85 of 1,304 (6.5%), propensity score matching.
risk of hospitalization/ER, 40.0% lower, RR 0.60, p = 0.003, treatment 40 of 652 (6.1%), control 133 of 1,304 (10.2%), propensity score matching.
SQ vs. IV death, 53.0% lower, RR 0.47, p = 0.52, treatment 1 of 969 (0.1%), control 3 of 1,216 (0.2%), adjusted.
SQ vs. IV death/hosp., 71.0% higher, RR 1.71, p = 0.06, treatment 27 of 969 (2.8%), control 21 of 1,216 (1.7%), adjusted.
SQ vs. IV hospitalization, 79.0% higher, RR 1.79, p = 0.05, treatment 27 of 969 (2.8%), control 20 of 1,216 (1.6%), adjusted.
SQ vs. IV ER/hosp., 15.0% lower, RR 0.85, p = 0.38, treatment 47 of 969 (4.9%), control 71 of 1,216 (5.8%), adjusted.
McCreary et al., 12/1/2021, prospective, USA, North America, preprint, 27 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Isa et al., medRxiv, doi:10.1101/2021.11.10.21265889 (Preprint) |
symp. case, ↓92.6%, p=0.002 |
Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19 |
|
Details
RCT 969 patients, 729 treated with monthly subcutaneous casirivimab/imdevimab, showing significantly lower risk of COVID-19 with treatment. There were no grade 3 injection site reactions or hypersensitivity reactions. Slightly more TEAEs .. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Isa et al., medRxiv, doi:10.1101/2021.11.10.21265889 (Preprint) |
| Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19 |
|
RCT 969 patients, 729 treated with monthly subcutaneous casirivimab/imdevimab, showing significantly lower risk of COVID-19 with treatment. There were no grade 3 injection site reactions or hypersensitivity reactions. Slightly more TEAEs were reported with treatment (54.9% vs. 48.3%), due to grade 1-2 ISRs. Serious adverse events were rare and occurred with similar percentages for treatment and control groups. There were no deaths. NCT04519437.
![]()
risk of symptomatic case, 92.6% lower, RR 0.07, p = 0.002, treatment 3 of 729 (0.4%), control 13 of 240 (5.4%), OR converted to RR.
risk of case, 92.7% lower, RR 0.07, p = 0.002, treatment 0 of 729 (0.0%), control 10 of 240 (4.2%), OR converted to RR, relative risk is not 0 because of continuity correction due to zero events, seroconversion.
Conflicts of interest:
employee of the drug patent holder.
Isa et al., 11/16/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 31 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Regeneron Press Release (News) |
hosp., ↓92.3%, p=0.03 |
New phase 3 analyses show that a single dose of REGEN-COV® (casirivimab and imdevimab) provides long-term protection against COVID-19 |
|
Details
Long-term results for PEP RCT NCT04452318, with 841 baseline seronegative casirivimab/imdevimab patients and 842 placebo patients, showing significantly lower cases with treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Regeneron Press Release (News) |
| New phase 3 analyses show that a single dose of REGEN-COV® (casirivimab and imdevimab) provides long-term protection against COVID-19 |
|
Long-term results for PEP RCT NCT04452318, with 841 baseline seronegative casirivimab/imdevimab patients and 842 placebo patients, showing significantly lower cases with treatment.
![]()
risk of hospitalization, 92.3% lower, RR 0.08, p = 0.03, treatment 0 of 841 (0.0%), control 6 of 842 (0.7%), relative risk is not 0 because of continuity correction due to zero events, 8 months.
risk of case, 81.5% lower, RR 0.19, p < 0.001, treatment 20 of 841 (2.4%), control 108 of 842 (12.8%), months 1-8.
risk of case, 81.6% lower, RR 0.18, p < 0.001, treatment 7 of 841 (0.8%), control 38 of 842 (4.5%), months 2-8.
risk of hospitalization/ER, 88.9% lower, RR 0.11, p = 0.06, treatment 0 of 753 (0.0%), control 4 of 752 (0.5%), relative risk is not 0 because of continuity correction due to zero events, day 29.
risk of symptomatic case, 81.4% lower, RR 0.19, p < 0.001, treatment 11 of 753 (1.5%), control 59 of 752 (7.8%), day 29.
recovery time, 62.5% lower, relative time 0.37, p < 0.001, treatment 753, control 752, short-term followup, relative time with symptoms.
time to viral-, 69.2% lower, relative time 0.31, p < 0.001, treatment 753, control 752, short-term followup, relative time with high viral load.
Regeneron et al., 11/8/2021, Double Blind Randomized Controlled Trial, multiple countries, multiple regions, preprint, 1 author.
|
|
Submit Corrections or Comments
|
|
N/A |
Kaleta et al., Research Square, doi:10.21203/rs.3.rs-995033/v1 (Preprint) |
Antibody escape and global spread of SARS-CoV-2 lineage A.27 |
|
Details
Anaysis of antibody escape showing variant A.27 completely escaped neutralization with LY-COV555 and partially with REGN10987. B.1.617.2 escaped these antibodies in a similar manner, suggesting that L452R facilitates the escape. Authors n.. |
|
Details
Source
PDF
N/A
N/A
|
| Kaleta et al., Research Square, doi:10.21203/rs.3.rs-995033/v1 (Preprint) |
| Antibody escape and global spread of SARS-CoV-2 lineage A.27 |
Anaysis of antibody escape showing variant A.27 completely escaped neutralization with LY-COV555 and partially with REGN10987. B.1.617.2 escaped these antibodies in a similar manner, suggesting that L452R facilitates the escape. Authors note that B.1.351 and P.1 escaped LY-COV555 and REGN10933, likely facilitated by the E484K mutation, suggesting that L452R and E484K lead to escape from LY-COV555 and to partial resistance to either REGN10987 or REGN10933, respectively.
![]()
Kaleta et al., 11/2/2021, preprint, 33 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Bierle et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab570 (preprint 10/20/2021) (Peer Reviewed) |
ICU, ↓88.9%, p=0.16 |
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities |
|
Details
Retrospective 1,395 vaccinated COVID-19 cases, showing significantly lower hospitalization and oxygen supplementation with monoclonal antibody treatment, primarily casirivimab-imdevimab. Hospitalization was significantly associated with c.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Bierle et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab570 (preprint 10/20/2021) (Peer Reviewed) |
| Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities |
|
Retrospective 1,395 vaccinated COVID-19 cases, showing significantly lower hospitalization and oxygen supplementation with monoclonal antibody treatment, primarily casirivimab-imdevimab. Hospitalization was significantly associated with comorbidities.
![]()
risk of ICU admission, 88.9% lower, RR 0.11, p = 0.16, treatment 0 of 527 (0.0%), control 5 of 868 (0.6%), relative risk is not 0 because of continuity correction due to zero events.
risk of oxygen therapy, 85.3% lower, RR 0.15, p < 0.001, treatment 5 of 527 (0.9%), control 56 of 868 (6.5%), OR converted to RR.
risk of hospitalization, 75.3% lower, RR 0.25, p < 0.001, treatment 14 of 527 (2.7%), control 93 of 868 (10.7%), OR converted to RR.
Excluded in meta analysis:
patients were treated with different medications, results specific to each medication were not reported.
Conflicts of interest:
research funding from the drug patent holder.
Bierle et al., 10/20/2021, retrospective, USA, North America, peer-reviewed, 7 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512 (Peer Reviewed) |
death, ↓77.5%, p=0.18 |
Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study |
|
Details
Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab. There was significantly lower hospitalization w.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512 (Peer Reviewed) |
| Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study |
|
Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab. There was significantly lower hospitalization with casirivimab-imdevimab compared to bamlanivimab or bamlanivimab-etesevimab. PSM and multivariate analysis is only provided for all treatments combined.
![]()
risk of death, 77.5% lower, RR 0.23, p = 0.18, treatment 1 of 1,148 (0.1%), control 33 of 8,534 (0.4%), unadjusted.
risk of ICU admission, 47.5% lower, RR 0.52, p = 0.14, treatment 6 of 1,148 (0.5%), control 85 of 8,534 (1.0%), unadjusted.
risk of hospitalization, 52.4% lower, RR 0.48, p < 0.001, treatment 45 of 1,148 (3.9%), control 703 of 8,534 (8.2%), unadjusted.
Excluded in after exclusion results of meta analysis:
unadjusted results with no group details.
Cooper et al., 10/8/2021, retrospective, USA, North America, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 (Peer Reviewed) |
death, ↓98.3%, p=0.63 |
Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19 |
|
Details
Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors falsely state that "no other COVID-19 therapies for ambulatory patient.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 (Peer Reviewed) |
| Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19 |
|
Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors falsely state that "no other COVID-19 therapies for ambulatory patients have proven effective".
![]()
risk of death, 98.3% lower, RR 0.02, p = 0.63, treatment 0 of 115 (0.0%), control 57 of 5,536 (1.0%), relative risk is not 0 because of continuity correction due to zero events.
risk of hospitalization, 91.1% lower, RR 0.09, p < 0.001, treatment 1 of 115 (0.9%), control 538 of 5,536 (9.7%).
Webb et al., 6/23/2021, retrospective, USA, North America, peer-reviewed, 14 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Horby et al., medRxiv, doi:10.1101/2021.06.15.21258542 (Preprint) |
death, ↓6.0%, p=0.17 |
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |
|
Details
RCT 9,785 hospitalized patients in the UK showing lower mortality with casirivimab/imdevimab, with statistical significance reached for baseline seronegative patients. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Horby et al., medRxiv, doi:10.1101/2021.06.15.21258542 (Preprint) |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |
|
RCT 9,785 hospitalized patients in the UK showing lower mortality with casirivimab/imdevimab, with statistical significance reached for baseline seronegative patients.
![]()
risk of death, 6.0% lower, RR 0.94, p = 0.17, treatment 944 of 4,839 (19.5%), control 1,026 of 4,946 (20.7%), all patients.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 479 of 4,556 (10.5%), control 487 of 4,642 (10.5%), all patients.
risk of death, 20.0% lower, RR 0.80, p = 0.001, treatment 396 of 1,633 (24.2%), control 451 of 1,520 (29.7%), seronegative patients.
risk of mechanical ventilation, 12.0% lower, RR 0.88, p = 0.18, treatment 189 of 1,599 (11.8%), control 200 of 1,484 (13.5%), seronegative patients.
Horby et al., 6/16/2021, Randomized Controlled Trial, United Kingdom, Europe, preprint, 34 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Weinreich et al., NEJM, doi:10.1056/NEJMoa2108163 (preprint 5/21/2021) (Peer Reviewed) |
death, ↓50.0%, p=0.45 |
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 |
|
Details
RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Weinreich et al., NEJM, doi:10.1056/NEJMoa2108163 (preprint 5/21/2021) (Peer Reviewed) |
| REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 |
|
RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629.
![]()
risk of death, 50.0% lower, RR 0.50, p = 0.45, treatment 2 of 2,091 (0.1%), control 4 of 2,089 (0.2%), Table S9.
risk of death, 67.0% lower, RR 0.33, p = 0.37, treatment 1 of 1,355 (0.1%), control 3 of 1,341 (0.2%), 2400mg,Table S9.
risk of death, 1.6% higher, RR 1.02, p = 1.00, treatment 1 of 736 (0.1%), control 1 of 748 (0.1%), 1200mg,Table S9.
risk of death/hospitalization, 71.3% lower, RR 0.29, p < 0.001, treatment 18 of 1,355 (1.3%), control 62 of 1,341 (4.6%), 2400mg.
risk of death/hospitalization, 70.4% lower, RR 0.30, p = 0.002, treatment 7 of 736 (1.0%), control 24 of 748 (3.2%), 1200mg.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 1,355, control 1,341, 2400mg.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 736, control 748, 1200mg.
Weinreich et al., 5/21/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 39 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
O'Brien et al., NEJM, doi:10.1056/NEJMoa2109682 (Peer Reviewed) |
hosp./ER, ↓88.9%, p=0.06 |
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 |
|
Details
Prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab. The same trial has updated results available in [1]. NCT04452318. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| O'Brien et al., NEJM, doi:10.1056/NEJMoa2109682 (Peer Reviewed) |
| Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 |
|
Prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab. The same trial has updated results available in [1]. NCT04452318.
![]()
risk of hospitalization/ER, 88.9% lower, RR 0.11, p = 0.06, treatment 0 of 753 (0.0%), control 4 of 752 (0.5%), relative risk is not 0 because of continuity correction due to zero events, day 29.
risk of symptomatic case, 81.4% lower, RR 0.19, p < 0.001, treatment 11 of 753 (1.5%), control 59 of 752 (7.8%), day 29.
recovery time, 62.5% lower, relative time 0.37, p < 0.001, treatment 753, control 752, relative time with symptoms.
time to viral-, 69.2% lower, relative time 0.31, p < 0.001, treatment 753, control 752, relative time with high viral load.
O'Brien et al., 4/12/2021, Double Blind Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 36 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Regeneron Press Release (Preprint) |
hosp./death, ↓71.3%, p<0.0001 |
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 |
|
Details
Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor.
Some variants may escape antibodies [1]. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Regeneron Press Release (Preprint) |
| New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 |
|
Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor.Some variants may escape antibodies [1].
![]()
risk of death/hospitalization, 71.3% lower, RR 0.29, p < 0.001, treatment 18 of 1,355 (1.3%), control 62 of 1,341 (4.6%), 2,400mg IV, >=1 risk factor.
risk of death/hospitalization, 70.4% lower, RR 0.30, p = 0.003, treatment 7 of 736 (1.0%), control 24 of 748 (3.2%), 1,200mg IV, >=1 risk factor.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 1,355, control 1,341, 2,400mg IV, >=1 risk factor.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 736, control 748, 1,200mg IV, >=1 risk factor.
Regeneron et al., 3/23/2021, Randomized Controlled Trial, USA, North America, preprint, 1 author.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Regeneron Press Release (Preprint) |
symp. case, ↓93.6%, p=0.009 |
Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 |
|
Details
Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/18.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Regeneron Press Release (Preprint) |
| Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 |
|
Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/186 REGEN-COV).
![]()
risk of symptomatic case, 93.6% lower, RR 0.06, p = 0.009, treatment 0 of 186 (0.0%), control 8 of 223 (3.6%), relative risk is not 0 because of continuity correction due to zero events.
risk of case, 47.9% lower, RR 0.52, p = 0.07, treatment 10 of 186 (5.4%), control 23 of 223 (10.3%).
Regeneron et al., 1/26/2021, Randomized Controlled Trial, USA, North America, preprint, 1 author.
|
|
Submit Corrections or Comments
|
|
Early |
Regeneron Press Release (Preprint) |
recov. time, ↓38.0%, p=0.22 |
Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients |
|
Details
Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Regeneron Press Release (Preprint) |
| Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients |
|
Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients that had not mounted their own effective immune response prior to treatment.The mean time-weighted-average change from baseline nasopharyngeal viral load through Day 7 in the seronegative (no measurable antiviral antibodies) group was a 0.60 log10 copies/mL greater reduction (p=0.03) in patients treated with high dose, and a 0.51 log10 copies/mL greater reduction (p=0.06) in patients treated with low dose, compared to placebo. In the overall population, there was a 0.51 log10 copies/mL greater reduction (p=0.0049) in patients treated with high dose, and a 0.23 log10 copies/mL greater reduction (p=0.20) in patients treated with low dose, compared to placebo.Among seronegative patients, median time to symptom alleviation (defined as symptoms becoming mild or absent) was 13 days in placebo, 8 days in high dose (p=0.22), and 6 days in low dose (p=0.09).Adverse reactions were similar with treatment and placebo. There were no deaths.
recovery time, 38.0% lower, relative time 0.62, p = 0.22, treatment 92, control 91, high dose median time to recovery, group sizes estimated because they were not supplied.
recovery time, 54.0% lower, relative time 0.46, p = 0.09, treatment 92, control 91, low dose median time to recovery, group sizes estimated because they were not supplied.
Regeneron et al., 9/29/2020, Randomized Controlled Trial, USA, North America, preprint, 1 author.
|
|
Submit Corrections or Comments
|
|
In Vitro |
Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) |
in vitro |
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies |
|
Details
In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve.. |
|
Details
Source
PDF
In Vitro
In Vitro
|
| Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) |
| Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies |
In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserved regions on the spike protein. However, escape mutants could not be efficiently generated following exposure to the REGN-COV2 cocktail since it utilizes two antibodies that can simultaneously bind to distinct regions of the RBD.
![]()
Baum et al., 8/21/2020, peer-reviewed, 17 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
|
|
Submit Corrections or Comments
|
|
Animal |
Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) |
animal study |
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail |
|
Details
Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on .. |
|
Details
Source
PDF
Animal study
Animal study
|
| Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) |
| Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail |
Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on the virus cell surface binds to the host cell and is required for infectivity. By blocking its interaction with the host cell, antibodies are able to neutralize the virus and block infection. Authors selected pairs of highly potent individual antibodies that simultaneously and non-competitively bind to the RBD. The multi-antibody approach is used to decrease the potential for the virus to escape.
![]()
Hansen et al., 8/21/2020, peer-reviewed, 47 authors.
|
|
Submit Corrections or Comments
|
